Nothing Special   »   [go: up one dir, main page]

BR112016013116A8 - inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas - Google Patents

inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas Download PDF

Info

Publication number
BR112016013116A8
BR112016013116A8 BR112016013116A BR112016013116A BR112016013116A8 BR 112016013116 A8 BR112016013116 A8 BR 112016013116A8 BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A BR112016013116 A BR 112016013116A BR 112016013116 A8 BR112016013116 A8 BR 112016013116A8
Authority
BR
Brazil
Prior art keywords
pharmaceutical compositions
pyrazolyl guanidine
atpase inhibitors
trifluoromethyl pyrazolyl
trifluoromethyl
Prior art date
Application number
BR112016013116A
Other languages
English (en)
Other versions
BR112016013116A2 (pt
Inventor
R Hurd Alexander
B Taylor Clarke
Wang Jian
Zhou Peng
Original Assignee
Lycera Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lycera Corp filed Critical Lycera Corp
Publication of BR112016013116A2 publication Critical patent/BR112016013116A2/pt
Publication of BR112016013116A8 publication Critical patent/BR112016013116A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4891—Coated capsules; Multilayered drug free capsule shells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/38—Nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Neurology (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Neurosurgery (AREA)
  • Obesity (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Vascular Medicine (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

a presente invenção fornece compostos de trifluorometil pirazolil guanidina que inibem f1f0-atpase, e métodos de usar compostos de trifluorometil pirazolil guanidina como agentes terapêuticos para tratar distúrbios médicos, tal como um distúrbio imune, condição inflamatória, ou câncer.
BR112016013116A 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas BR112016013116A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361914085P 2013-12-10 2013-12-10
US201461979619P 2014-04-15 2014-04-15
PCT/US2014/069487 WO2015089149A1 (en) 2013-12-10 2014-12-10 Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof

Publications (2)

Publication Number Publication Date
BR112016013116A2 BR112016013116A2 (pt) 2017-08-08
BR112016013116A8 true BR112016013116A8 (pt) 2020-05-12

Family

ID=53371791

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016013116A BR112016013116A8 (pt) 2013-12-10 2014-12-10 inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas

Country Status (10)

Country Link
US (4) US9266839B2 (pt)
EP (1) EP3080089B1 (pt)
JP (1) JP6486364B2 (pt)
CN (1) CN105899489A (pt)
AU (1) AU2014363904B2 (pt)
BR (1) BR112016013116A8 (pt)
CA (1) CA2931851A1 (pt)
IL (1) IL245930A0 (pt)
MX (1) MX2016007445A (pt)
WO (1) WO2015089149A1 (pt)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI2648511T1 (sl) 2010-12-08 2017-11-30 Lycera Corporation Pirazolil gvanidinski inhibitorji F1F0-ATPaze in njihove terapevtske uporabe
WO2012078869A1 (en) 2010-12-08 2012-06-14 Lycera Corporation Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
WO2013185045A1 (en) 2012-06-08 2013-12-12 Lycera Corporation Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
EP2861225A4 (en) 2012-06-08 2015-11-18 Lycera Corp Saturated acylguanidine for the inhibition of F1F0-ATPASE
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof
EP3080087B1 (en) 2013-12-10 2019-05-22 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
AU2014363958B2 (en) 2013-12-10 2018-11-08 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
CN116570589A (zh) * 2023-05-30 2023-08-11 南阳理工学院 化合物Parimifasor在制备抗肿瘤药物中的应用

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4977189A (en) * 1986-05-07 1990-12-11 American Cyanamid Company Substituted guanidinedicarbonyl derivatives
JPH07188197A (ja) 1993-11-17 1995-07-25 Fujisawa Pharmaceut Co Ltd オキサゾール誘導体
DE4344550A1 (de) 1993-12-24 1995-06-29 Hoechst Ag Substituierte 1-Oxo-1,2-dihydro-isochinolinoyl- und 1,1-Dioxo-2H-1,2-benzothiazinoylguanidine, Verfahrenzu ihrer Herstellung, ihre Verwendung als Medikamentt oder Diagnostikum sowie sie enthaltendes Medikamen
US7041702B1 (en) 1997-10-21 2006-05-09 Scion Pharmaceuticals, Inc. Pharmaceutically active compounds and methods of use
JP2002536411A (ja) 1999-02-09 2002-10-29 ブリストル−マイヤーズ スクイブ カンパニー Ｘａ因子のラクタム系阻害剤および方法
US7276348B2 (en) 1999-04-30 2007-10-02 Regents Of The University Of Michigan Compositions and methods relating to F1F0-ATPase inhibitors and targets thereof
AU5852300A (en) 1999-07-15 2001-02-05 Sumitomo Pharmaceuticals Company, Limited Heteroaromatic ring compounds
IL153123A0 (en) 2000-06-30 2003-06-24 Bristol Myers Squibb Co N-ureidoheterocycloalkyl-piperidine derivatives and pharmaceutical compositions containing the same
EP1450901A4 (en) 2001-12-10 2005-05-25 Bristol Myers Squibb Co (1-PHENYL-2-HETEROARYL) ETHYL-GUANIDINE COMPOUNDS AS AN INHIBITORS OF MITOCHONDRIAL F1F0 ATP HYDROLASE
GB0208224D0 (en) 2002-04-10 2002-05-22 Celltech R&D Ltd Chemical compounds
AU2003276648A1 (en) 2002-06-17 2003-12-31 Bristol-Myers Squibb Company Benzodiazepine inhibitors of mitochondial f¿1?f¿0? atp hydrolase and methods of inhibiting f¿1?f¿0? atp hydrolase
US7109224B2 (en) 2002-11-06 2006-09-19 Bristol-Myers Squibb Co. Acyl guanidine compounds and use thereof
ATE440827T1 (de) 2002-12-04 2009-09-15 Ore Pharmaceuticals Inc Melanocortin-rezeptormodulatoren
DE102004008141A1 (de) 2004-02-19 2005-09-01 Abbott Gmbh & Co. Kg Guanidinverbindungen und ihre Verwendung als Bindungspartner für 5-HT5-Rezeptoren
US20090275099A1 (en) 2004-04-27 2009-11-05 Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US20050272723A1 (en) 2004-04-27 2005-12-08 The Regents Of The University Of Michigan Methods and compositions for treating diseases and conditions associated with mitochondrial function
US7872005B2 (en) 2004-07-01 2011-01-18 Synta Pharmaceuticals Corporation 2-substituted heteroaryl compounds
NZ573452A (en) 2006-06-09 2011-09-30 Univ Michigan Compositions and methods relating to novel compounds and targets thereof
AU2008298870C1 (en) 2007-09-14 2014-10-09 The Regents Of The University Of Michigan F1F0-ATPase inhibitors and related methods
EP2219646A4 (en) 2007-12-21 2010-12-22 Univ Rochester METHOD FOR MODIFYING THE LIFETIME OF EUKARYOTIC ORGANISMS
KR100982661B1 (ko) 2008-04-22 2010-09-17 전남대학교산학협력단 플라스멥신 ⅱ 활성을 저해하는 화합물을 유효성분으로함유하는 말라리아 예방 및 치료를 위한 약학 조성물 및이를 이용한 말라리아 치료방법
US8497307B2 (en) 2008-09-11 2013-07-30 The Regents Of The University Of Michigan Aryl guanidine F1F0-ATPase inhibitors and related methods
WO2012078869A1 (en) 2010-12-08 2012-06-14 Lycera Corporation Pyridonyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
AU2011338302A1 (en) 2010-12-08 2013-07-11 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
US9169199B2 (en) 2010-12-08 2015-10-27 Lycera Corporation Cycloalkyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
SI2648511T1 (sl) 2010-12-08 2017-11-30 Lycera Corporation Pirazolil gvanidinski inhibitorji F1F0-ATPaze in njihove terapevtske uporabe
US9221814B2 (en) 2012-06-08 2015-12-29 Lycera Corporation Heterocyclic guanidine F1F0-atpase inhibitors and therapeutic uses thereof
WO2013185045A1 (en) * 2012-06-08 2013-12-12 Lycera Corporation Indazole guanidine f1f0-atpase inhibitors and therapeutic uses thereof
EP2861225A4 (en) 2012-06-08 2015-11-18 Lycera Corp Saturated acylguanidine for the inhibition of F1F0-ATPASE
EP3080087B1 (en) 2013-12-10 2019-05-22 Lycera Corporation N-substituted pyrazolyl guanidine f1f0-atpase inhibitors and therapeutic uses thereof
AU2014363958B2 (en) * 2013-12-10 2018-11-08 Lycera Corporation Alkylpyrazolyl guanidine F1F0-ATPase inhibitors and therapeutic uses thereof
EP3080089B1 (en) 2013-12-10 2019-05-08 Lycera Corporation Trifluoromethyl pyrazolyl guanidine f1fo-atpase inhibitors and therapeutic uses thereof

Also Published As

Publication number Publication date
CA2931851A1 (en) 2015-06-18
US9266839B2 (en) 2016-02-23
MX2016007445A (es) 2016-09-09
JP6486364B2 (ja) 2019-03-20
US20160287559A1 (en) 2016-10-06
US20150183745A1 (en) 2015-07-02
US9707211B2 (en) 2017-07-18
US10085972B2 (en) 2018-10-02
BR112016013116A2 (pt) 2017-08-08
AU2014363904A1 (en) 2016-06-30
EP3080089A1 (en) 2016-10-19
IL245930A0 (en) 2016-08-02
WO2015089149A1 (en) 2015-06-18
EP3080089A4 (en) 2017-08-23
EP3080089B1 (en) 2019-05-08
AU2014363904B2 (en) 2018-10-04
CN105899489A (zh) 2016-08-24
US20190175556A1 (en) 2019-06-13
JP2016539985A (ja) 2016-12-22
US20170354643A1 (en) 2017-12-14

Similar Documents

Publication Publication Date Title
BR112016013116A8 (pt) inibidores de trifluorometil pirazolil guanidina f1f0-atpase, seus usos, e composições farmacêuticas
SV2015005066A (es) Compuestos de biaril-amida como inhibidores de cinasa
CY1122098T1 (el) Παραγωγα ισοχρωμενιου ως αναστολεις κινασων φωσφοϊνοσιτιδης-3
BR112018010464A8 (pt) formulações farmacêuticas tópicas para tratar condições inflamatórias relacionadas
PH12016501139B1 (en) Bicyclic heterocycle compounds and their uses in therapy
NI201600071A (es) Compuestos de inhibidor de autotaxina
BR112018000624A2 (pt) compostos de indazol e azaindazol como inibidores de irak-4
SV2016005180A (es) Amino-heteroaril-benzamidas como inhibidores de cinasa
MA40437A (fr) Méthodes de traitement du cancer faisant appel à des inhibiteurs de tigit et à des agents anticancéreux
BR112017006940A2 (pt) triazolopirazinonas como inibidores de pde1
ECSP14030779A (es) Inhibidores del nampt
GT201600027A (es) Inhibidores de rorc2 y sus métodos de uso
BR112017009552A8 (pt) Métodos para alvejar o controle transcricional em regiões de super-realçador
PL410665A1 (pl) Inhibitory arginazy oraz ich zastosowania terapeutyczne
MX344590B (es) Inhibidores de f1f0-atpasas de tipo pirazolilguanidina y sus usos terapéuticos.
NI201600070A (es) Inhibidores tetracíclicos de autotaxina
WO2013185048A3 (en) Heterocyclic guanidine f1f0-atpase inhibitors
MX2013006398A (es) Inhibidores de f1f0-atpasas de tipo piridonilguanidina y usos terapeúticos.
BR112017024908A2 (pt) usos terapêuticos da 4-cloroquinurenina
EA201691108A1 (ru) Хиназолин-thf-амины в качестве ингибиторов pde1
EA201592012A8 (ru) Применение флагеллина для улучшенной химиотерапии
AU2014353885A8 (en) Prevention and treatment of toxicosis
AR122753A2 (es) Inhibidores selectivos de proteínas cinasas delta pi3k, composiciones farmacéuticas, usos, y métodos de tratamiento y/o prevención de las enfermedades o trastornos mediados por cinasas
PH12020500472A1 (en) Autotaxin inhibitor compounds
BR112017012931A2 (pt) métodos para redução de agregação plaquetária e tratamento de doença cardiovascular e outros distúrbios médicos

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements